Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 3, 2012, Pages 273-277

  Youssef, Ramy F ^a   Schlomer, Bruce J ^a   Ho, Richard ^a   Sagalowsky, Arthur I ^a   Ashfaq, Raheela ^a   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

FISH assay; Negative cytology; Urothelial carcinoma of the bladder; UroVysion

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CYSTOSCOPY; CYTOLOGY; DISEASE SEVERITY; FALSE NEGATIVE RESULT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CYSTOSCOPY; CYTOLOGICAL TECHNIQUES; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84860303219     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.02.012     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Hong Y.M., Loughlin K.R. Economic impact of tumor markers in bladder cancer surveillance. Urology 2008, 71:131-135.
3. van Rhijn B.W., Burger M., Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009, 56:430-442.
4. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314.
5. Halling K.C., King W., Sokolova I.A., et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000, 164:1768-1775.
6. Lotan Y., Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers vs. cytology: Results of a comprehensive literature review and meta-analyses. Urology 2003, 61:109-118.
7. Lotan Y., Bensalah K., Ruddell T., et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008, 179:2164-2169.
8. Pycha A. FISH: A tool we really need?. Eur Urol 2007, 52:630-632.
9. Sarosdy M.F., Kahn P.R., Ziffer M.D., et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006, 176:44-47.
10. Skacel M., Fahmy M., Brainard J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003, 169:2101-2105.
11. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005, 66(6 Suppl 1):35-63.
12. Schlomer B.J., Ho R., Sagalowsky A., et al. Prospective validation of the clinical utility of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2010, accepted for publication.
13. Yoder B.J., Skacel M., Hedgepeth R., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: A prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007, 127:295-301.
14. Daniely M., Rona R., Kaplan T., et al. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology 2005, 66:1354-1359.
15. Guney S., Guney N., Canogullari Z., et al. Ta T1 low and intermediate transitional cell carcinoma of the bladder: Recurrence rates and the timing of check cystoscopies within the first year. Urol Int 2008, 80:124-128.
16. Oge O., Erdem E., Atsü N., et al. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. Eur Urol 2000, 37:271-274.
17. Sarosdy M.F., Schellhammer P., Bokinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002, 168:1950-1954.
18. Laudadio J., Keane T.E., Reeves H.M., et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: Implications for clinical practice. BJU Int 2005, 96:1280-1285.
19. Nguyen C.T., Litt D.B., Dolar S.E., et al. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer. Urology 2009, 73:347-350.
20. Ferra S., Denley R., Herr H., et al. Reflex UroVysion testing in suspicious urine cytology cases. Cancer Cytopathol 2009, 117:7-14.